Trial No.: JANSSEN 54767414 MMY3019
A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy.
Trial No.: Janssen 54767414 MMY3021 “Auriga”
A Randomized Study of Daratumumab plus Lenalidomide vs. Lenalidomide Alone vs Maintenance Treatment in Patients with Newly Diagnosed Mulitple Myeloma Who Are Minimal Residual Disease Positive after Frontline Autologous Stem Cell Transplant.
Trial No.: Janssen 54767414 MMY2065 “Lynx”
A Phase 2 Study Comparing Daratumumab Subcutaneous Administration in Combination with Carfilzomib, and Dexamethasone (DKd) vs Carfilzomib and Dexamethasone (Kd) in Subjects with Multiple Myeloma who have been Previously treated with Daratumumab IV.
©2019 Fort Wayne Medical Oncology and Hematology. All Rights Reserved.